Bright Green Operational UpdateGRANTS, N.M., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or “the Company”), one of the few companies selected by the U.S. government to grow, manufacture, and sell, legally under both federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that specific plants have now been selected for the test crops at its Grants New Mexico facility, and the company gives its operational updates.
Bright Green announces plans to launch a program to support as many as 170 universities for cannabis research in the United States as well as an extension of the Company’s EB-5 initiative to enable foreign students attending universities in the UnitedThe Company plans to foster relationships with learning institutes across the U.S. to enhance the application of scientific discipline to the field of medical and pharmaceutical cannabinoid therapies and to build upon this unique EB-5 initiative for capital moving forward.
Bright Green Announces it has been added to the Russell 3000® Index following the Annual ReconstitutionThe Company views the development as an additional milestone building on its key strategic achievement in 2023 already including its historic DEA registration and confirmation of its EB-5 program.
Bright Green Announces Closing of $3.5 Million Private PlacementGRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:
BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications, and affiliated export, today announced the closing of its previously announced private placement of common stock and warrants.
Bright Green Announces First Quarter 2023 Financial Update and Milestone ProgressBright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval.
Bright Green Announces Pricing of $3.5 Million Private PlacementGRANTS, N.M., May 22, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:
BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,684,210 shares of common stock and warrants to purchase up to 3,684,210 shares of common stock, at a purchase price of $0.95 per share and accompanying warrant. The gross proceeds to the Company from the private placement are expected to be approximately $3.5 million before deducting the placement agent's fees and other estimated offering expenses.
Bright Green Announces the Launch of Its EB-5 Website and Program Following the Historic Announcement of Its Federal Registration and License Approval from the U.S. Drug Enforcement AdministrationBright Green, the first publicly traded company in the U.S. to be federally authorized to grow, manufacture and sell cannabis and cannabis-related products for research, pharmaceutical and medical applications, can qualify for the EB-5 program and plans to raise $500 million in new capital
Bright Green Announces Historic Federal Registration and License Approval from the U.S. Drug Enforcement Administration Confirming Bright Green as a Bulk Manufacturer of CannabisBright Green is now the first publicly traded company, and the largest, in the U.S. to be federally authorized to grow, manufacture and sell cannabis and cannabis-related products for research, pharmaceutical applications and affiliated import and export
Bright Green Announces Fourth Quarter 2022 Financial UpdateContinued investment to support long-term strategy and pathway for growth, including plans to fully acquire Alterola Biotech, appointment of Seamus McAuley as Chief Executive Officer and expansion of Scientific Advisory Board
Bright Green Responds to False Claims Made Against the CompanyDenies any association with John Fikany and Jerry Capussi and categorically refutes the insinuations made on behalf of these individuals
Bright Green Announces the Receipt of Its First Funds from Its EB-5 ProgramNews reinforces Bright Green’s plans to build additional new facilities in Grants, New Mexico, and confirms final requirements and amendments to certificate of occupancy for existing one million square foot greenhouse
Bright Green Issues Statement of Intent on Illegal Short Selling ActivitiesGRANTS, N.M., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:
BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced it has begun a review of the trading patterns of the Company's common stock since its listing and will monitor the stock activity going forward. The Company values its shareholders and wants to have all available data at its disposal to act in its fiduciary capacity.
Bright Green Announces Plans to Raise $500 Million Under EB-5 Capital ProgramCapital raised from EB-5 Program projected to generate over 7,100 direct and induced jobs in New Mexico and across the U.S.
Bright Green Provides Update on Progress as It Prepares for Multiple Activities in 2023GRANTS, N.M., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:
BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today provided an update on progress on the execution of its business plan and the developments ahead for 2023.
Bright Green Announces Third Quarter 2022 Financial Update and Milestone ProgressBright Green reaches several key milestones, advancing progress against its strategic plan
Bright Green Strengthens its Scientific Advisory Board with the Appointment of Five Additional Biotech and Pharmaceutical LeadersExpansion of Bright Green’s Scientific Advisory Board supports its mission to be the premier federally-authorized provider of cannabis and derivative products
Bright Green Announces Close of Transaction with Alterola BiotechBright Green acquired 25% of Alterola’s issued and outstanding common stock
